Healthcare / Medical Instruments & SuppliesTokyo
$1982.50
+30.00 (+1.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $16.2B · quality 73.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$182.4B
P/E
14.0x
↓EV/EBITDA
4.6x
↓ROE
10.1%
↑Gross Margin
9.8%
↓Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.7%
FCF CAGR
+21.8%
FCF margin
2.4%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $678.23B · net income $15.13B · FCF $16.20B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $678.23B | $678.23B | $630.99B | $572.28B | $514.35B |
| Net Income | $15.13B | $15.13B | $13.80B | $12.06B | $12.17B |
| EBITDA | $32.20B | $32.20B | $29.75B | $28.54B | $26.57B |
| EPS | 21.54 | 21.54 | 146.15 | 115.92 | 117.01 |
| Gross Margin | 9.8% | 9.8% | 10.4% | 10.6% | 10.4% |
| Operating Margin | 3.7% | 3.7% | 3.9% | 3.7% | 4.0% |
| Net Margin | 2.2% | 2.2% | 2.2% | 2.1% | 2.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.42 | 0.58 | 0.52 |
| Current Ratio | 1.38 | 1.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.20B | $16.20B | $28.09B | $10.20B | $8.96B |
| Returns | |||||
| ROE | 10.1% | 10.1% | 9.9% | 9.4% | 10.3% |
| Valuation | |||||
| P/E | 13.96 | 13.96 | 13.92 | 20.70 | 17.54 |
| EV/EBITDA | 4.64 | 4.64 | 5.54 | 8.51 | 7.56 |
| P/B | 1.27 | 1.27 | 1.38 | 1.95 | 1.80 |
| Growth & Yield | |||||
| Revenue Growth | 7.5% | 7.5% | 10.3% | 11.3% | — |
| EPS Growth | -85.3% | -85.3% | 26.1% | -0.9% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
101.4%
EPS terminal req.
$175.91
Spread vs growth
-186.6%
5Y implied EPS CAGR
58.1%
EPS terminal req.
$212.86
Spread vs growth
-143.4%
10Y implied EPS CAGR
31.9%
EPS terminal req.
$342.81
Spread vs growth
-117.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+15.8%
Start / end P/E
12.2x → 93.4x
EPS bridge
146.15 → 21.54
Residual
-565.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.